RPRX Royalty Pharma plc
Healthcare$53.86-1.17%ClosedMarket Cap: $23.17B
As of 2026-05-26
Valuation
P/E (TTM)
26.05
PEG
—
P/B
3.42
P/S
9.61
EV/EBITDA
17.98
DCF Value
$25.75
FCF Yield
11.3%
Div Yield
1.7%
Margins & Returns
Gross Margin
100.0%
Operating Margin
67.9%
Net Margin
33.9%
ROE
12.7%
ROA
4.2%
ROIC
8.4%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $630.6M | 99.8% | $632.5M | $295.0M | $— | $0.24 |
| Q4 null | $622.0M | 100.0% | $388.4M | $214.2M | $— | $0.22 |
| FY null | $2.38B | 100.0% | $1.56B | $770.9M | $— | $0.88 |
| Q3 null | $609.3M | 100.0% | $427.2M | $288.2M | $— | $0.22 |
| Q2 null | $578.7M | 100.0% | $209.8M | $30.2M | $— | $0.22 |
| Q1 null | $568.2M | 100.0% | $534.2M | $238.3M | $— | $0.22 |
| Q4 null | $593.6M | 100.0% | $361.5M | $208.2M | $— | $0.21 |
| FY null | $2.26B | 100.0% | $1.29B | $859.0M | $— | $0.84 |
| Q3 null | $564.7M | 100.0% | $735.1M | $544.0M | $— | $0.21 |
| Q2 null | $537.3M | 100.0% | $269.6M | $102.0M | $— | $0.21 |
| Q1 null | $568.0M | 100.0% | $-73.8M | $4.8M | $— | $0.21 |
| Q4 2023 | $596.1M | 100.0% | $612.9M | $494.3M | $1.10 | $0.20 |